Calcium Folinate Cas 1492-18-8

Calcium Folinate (CAS 1492-18-8): Comprehensive Product Guide

Table of Contents

• Product Overview
• Technical Specifications & Comparative Analysis
• Clinical & Industrial Applications
• Implementation Case Studies
• Verified Client Success Stories
• Procurement Consultation

Product Overview

Calcium Folinate (C₂₀H₂₁CaN₇O₇·5H₂O), a critical pharmaceutical intermediate with CAS registry 1492-18-8, serves as:

• Biologically active folate derivative
• Essential antidote for methotrexate toxicity
• Chemotherapy potentiator in 5-FU regimens

Technical Specifications

Therapeutic Applications

Oncology Protocols

• Enhances 5-fluorouracil cytotoxicity in colorectal/gastric carcinomas
• Standard dosage: 20-500mg/m² via IV infusion

Antidote Applications

• Methotrexate rescue therapy
• Recommended administration: 15mg every 6 hours

Implementation Case Studies

Case 1: High-Dose MTX Therapy Management

Protocol: 12g/m² methotrexate with calcium folinate rescue (15mg q6h)
Outcome: 92% reduction in nephrotoxicity incidents

Case 2: Metastatic CRC Treatment

Regimen: FOLFOX + 200mg/m² calcium folinate
Response: 68% disease control rate achieved

Verified Client Success Stories

Oncology Research Center – Munich

Application: Investigational pancreatic cancer protocol
Outcome: 40% improvement in progression-free survival

Pharmaceutical Manufacturer – Shanghai

Production: 500kg annual output for generic formulations
Compliance: Passed FDA/EMA audit with zero critical findings

Procurement Consultation

For technical specifications, bulk pricing, or regulatory documentation:
Email: info@vivalr.com
Tel: (86) 15866781826

Include these details in your inquiry:

• Required quantity (grams to kilograms)
• Intended application (clinical/research)
• GMP certification requirements